MAPT and Alzheimer disease: Recently, the Lumipulse G plasma p-Tau217/Aβ1–42 ratio blood test was shown to detect abnormal Aβ- and Tau-positron emission tomography (PET) with high accuracy [20] and became the first blood test for AD diagnosis to be approved by the U.S. Food and Drug Administration [21].